FindTrial
Sign In

Does treatment with repeated doses of albendazole reduce hookworm reinfection rates in an endemic tribal population?

Comparison of efficacy of single or multiple cycle(s) of preventive chemotherapy with albendazole in reducing the hookworm reinfection rate in an endemic tribal population

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2013/05/003676
Enrollment
1350
Registered
2013-05-24
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Albendazole 400 mg: Intervention 1: Two MDA cycles with 400 mg albendazole, one month apart. Intervention2: Albendazole 400 mg: Intervention 2: Four MDA cycles with 400 mg albendazole â

Sponsors

Christian Medical College Vellore
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Permanent resident of the village 2. Willing to stay in the area for the duration of follow-up 3. Willing to have study personnel visit at home

Exclusion criteria

Exclusion criteria: 1. Individuals with syndromic or serological evidence of HIV infection or immunocompromise 2. Individuals who have received albendazole within the last 6 months 3. Pregnant women, individuals with a history of seizure, epilepsy or known neurological disorder

Design outcomes

Primary

MeasureTime frame
Reduction in the number of infected people (cure rate, CR)Timepoint: One year post-treatment—

Secondary

MeasureTime frame
Reduction in faecal egg counts (FECR)Timepoint: After each cycle of albendazole, and one year post-treatment—

Countries

India

Contacts

Public ContactRajiv Sarkar

Christian Medical College, Vellore

gkang@cmcvellore.ac.in

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 17, 2026